AFM
GALT icon

Anson Funds Management’s Galectin Therapeutics GALT Stock Holding History

Anson Funds Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-56,288
Closed -$195K – 49
2014
Q4 		$195K Buy
+56,288
New +$249K 0.23% 40

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Anson Funds Management's GALT Position: Q1 2015 in Review

Anson Funds Management sold out of Galectin Therapeutics (GALT) in Q1 2015, closing a stake of 56,288 shares — an estimated $195K sold.

Anson Funds Management first reported a position in GALT in Q4 2014 and held it in 1 quarter. The position peaked at $195K in Q4 2014. 62 funds tracked by Wall St. Rank hold GALT as of Q1 2015.

  • Anson Funds Management reported no remaining Galectin Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Anson Funds Management sold 56,288 Galectin Therapeutics shares in Q1 2015, an estimated $195K.
  • Anson Funds Management first reported a position in Galectin Therapeutics in Q4 2014 and held it in 1 quarter.
  • Anson Funds Management's Galectin Therapeutics position peaked at $195K in Q4 2014.
  • 62 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2015.

Based on Anson Funds Management's 13F filing for Q1 2015, filed 15 May 2015.